Sugi Predict

Sugi Predict / Targets / CACNA1A

CACNA1A

Voltage-dependent P/Q-type calcium channel subunit alpha-1A · O00555 · CACNA1A on Sugi Atlas →

9,541 patent compounds predicted against CACNA1A, 4,837 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL116362 SCHEMBL116362 0.45 11/20
SCHEMBL2585915 SCHEMBL2585915 0.51 8/20
SCHEMBL3354274 SCHEMBL3354274 0.62 7/20
SCHEMBL3357851 SCHEMBL3357851 0.54 7/20
SCHEMBL3350921 SCHEMBL3350921 0.49 7/20
SCHEMBL619154 SCHEMBL619154 0.41 7/20
SCHEMBL620978 SCHEMBL620978 0.40 7/20
SCHEMBL621013 SCHEMBL621013 0.40 7/20
SCHEMBL621555 SCHEMBL621555 0.39 6/20
SCHEMBL617973 SCHEMBL617973 0.38 6/20
SCHEMBL1810921 SCHEMBL1810921 0.51 5/20
SCHEMBL3353571 SCHEMBL3353571 0.47 5/20
SCHEMBL3248439 SCHEMBL3248439 0.45 5/20
SCHEMBL620400 SCHEMBL620400 0.44 5/20
SCHEMBL620595 SCHEMBL620595 0.44 5/20
SCHEMBL619405 SCHEMBL619405 0.43 5/20
SCHEMBL3468836 SCHEMBL3468836 0.42 5/20
SCHEMBL618375 SCHEMBL618375 0.37 5/20
SCHEMBL3356257 SCHEMBL3356257 0.58 4/20
SCHEMBL2034740 SCHEMBL2034740 0.46 4/20

Clinical trials — most relevant to CACNA1A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination PHASE4UNKNOWN
Role of Intralipid in Management of Organophosphorus Poisoning PHASE2/PHASE3WITHDRAWN
4-Aminopyridine in Episodic Ataxia Type 2 PHASE2WITHDRAWN
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome PHASE1/PHASE2NOT_YET_RECRUITING
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients PHASE2WITHDRAWN
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients PHASE2WITHDRAWN
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain PHASE2COMPLETED
Verapamil as Therapy for Children and Young Adults With Dravet Syndrome PHASE2COMPLETED
Pathophysiology Based Therapy of Early Onset Epileptic Encephalopathies PHASE2WITHDRAWN
Physiologic Effects of Topiramate on Cognition PHASE1COMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development nanRECRUITING
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study nanUNKNOWN
Evaluation of A Clinical Diagnostic Test for CRDS nanRECRUITING
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
Verapamil in Supraclavicular Brachial Plexus Block nanUNKNOWN
International CRDS Registry nanRECRUITING
The Use of Antiarrhythmic Drugs in Pediatrics nanUNKNOWN
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY) nanCOMPLETED
Post-stroke Epilepsy: Primary Prophylaxis Study nanUNKNOWN
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. nanUNKNOWN
Multicenter Study of Patients With SHANK3 Mutations: Identification of Genes Modificators in Phelan-McDermid Syndrome (EUQ13) nanNOT_YET_RECRUITING
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services nanUNKNOWN
Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of Malignant Hyperthermia nanCOMPLETED
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
A Single Center Prospective Study in an Estimated 570 Patients Who Underwent Genetic Screening at UZ Brussel in the Context of a Primary Cardiac Arrhythmia. Patients Showing a Variant Class 3,4 or 5 in SCN4A or CLCN1 Will Undergo a Clinical and Electrophysiological Review After IC. nanNOT_YET_RECRUITING
Early Detection of Cardiomyopathy by Speckle Echo, High Sensitive Troponin and Cardiac Ryanodine Receptors nanUNKNOWN
CACP: Study on Camptodactyly - Arthropathy - Coxa Vara - Pericarditis (CACP) Syndrome nanRECRUITING
The Prevalence of RYR1-related Disease nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a CACNA1A binder may also engage these)

ProteinNameSimilarity
P54282 — 1.000 P54282 →
P97445 — 1.000 P97445 →
P27884 — 1.000 P27884 →
CACNA1B Voltage-dependent N-type calcium channel subunit alpha-1B 1.000 landscape →
Q02294 — 1.000 Q02294 →
Q05152 — 1.000 Q05152 →
O55017 — 1.000 O55017 →
Q61290 — 1.000 Q61290 →
P56698 — 1.000 P56698 →
Q07652 — 0.999 Q07652 →
P27732 — 0.998 P27732 →
P15381 — 0.997 P15381 →
CACNA1E Voltage-dependent R-type calcium channel subunit alpha-1E 0.997 landscape →
CACNA1C Voltage-dependent L-type calcium channel subunit alpha-1C 0.997 landscape →
P56699 — 0.997 P56699 →
O73700 — 0.997 O73700 →
CACNA1H Voltage-dependent T-type calcium channel subunit alpha-1H 0.996 landscape →
CACNA1D Voltage-dependent L-type calcium channel subunit alpha-1D 0.995 landscape →
CACNA1I Voltage-dependent T-type calcium channel subunit alpha-1I 0.995 landscape →
Q62968 — 0.994 Q62968 →
O35505 — 0.994 O35505 →
C9D7C2 — 0.993 C9D7C2 →
Q02343 — 0.993 Q02343 →
Q6QIY3 — 0.993 Q6QIY3 →
P22002 — 0.992 P22002 →
Q02789 — 0.992 Q02789 →
Q01815 — 0.992 Q01815 →
CACNA1G Voltage-dependent T-type calcium channel subunit alpha-1G 0.991 landscape →
Q9JJV9 — 0.991 Q9JJV9 →
Q28644 — 0.991 Q28644 →